Citations (49)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Massimiliano Buoli, Marta Serati, Valentina Ciappolino & A. Carlo Altamura. (2016) May selective serotonin reuptake inhibitors (SSRIs) provide some benefit for the treatment of schizophrenia?. Expert Opinion on Pharmacotherapy 17:10, pages 1375-1385.
Read now
Read now
Teruo Hayashi, Shang-Yi Tsai, Tomohisa Mori, Michiko Fujimoto & Tsung-Ping Su. (2011) Targeting ligand-operated chaperone sigma-1 receptors in the treatment of neuropsychiatric disorders. Expert Opinion on Therapeutic Targets 15:5, pages 557-577.
Read now
Read now
IvanD. Montoya & Frank Vocci. (2007) Medications Development for the Treatment of Nicotine Dependence in Individuals with Schizophrenia. Journal of Dual Diagnosis 3:3-4, pages 113-150.
Read now
Read now
Articles from other publishers (46)
Arnim Johannes Gaebler, Ekkehard Haen, Nagia Ben Omar, Katharina Endres, Christoph Hiemke, Georgios Schoretsanitis & Michael Paulzen. (2023) Lower sertraline plasma concentration in patients co‐medicated with clozapine—Implications for pharmacological augmentation strategies in schizophrenia. Pharmacology Research & Perspectives 11:2.
Crossref
Crossref
William J. FreedWilliam J. Freed. 2022. Motivation and Desire. Motivation and Desire
197
208
.
Loïc Carment, Lucile Dupin, Laura Guedj, Maxime Térémetz, Macarena Cuenca, Marie-Odile Krebs, Isabelle Amado, Marc A. Maier & Påvel G. Lindberg. (2020) Neural noise and cortical inhibition in schizophrenia. Brain Stimulation 13:5, pages 1298-1304.
Crossref
Crossref
Saeed Shoja Shafti. (2019) Systematic Review of Local Studies Regarding Efficiency of Add-On Medications on Negative Symptoms of Schizophrenia: A Meta-Analysis. Current Psychopharmacology 8:2, pages 113-122.
Crossref
Crossref
Chao Zhou, Jiu Chen, Xiaowei Tang, Xiaotang Feng, Miao Yu, Weiwei Sha, Xiang Wang, Xiaobin Zhang, Hongwei Yi & Xiangrong Zhang. (2018) DNA methylation and gene expression of the chemokine (C-X-C motif) ligand 1 in patients with deficit and non-deficit schizophrenia. Psychiatry Research 268, pages 82-86.
Crossref
Crossref
I. Uhl, A. Kulik, P. Roser, A. Theodoridou, C. Wyss, C. Norra, M. Brüne, W. Kawohl & G. Juckel. (2018) Central serotonergic function in patients with predominantly negative symptoms of schizophrenia. Schizophrenia Research 193, pages 443-444.
Crossref
Crossref
Cornelis J. Van der Schyf. (2016) Psychotropic Drug Development Strategies that Target Neuropsychiatric Etiologies in Alzheimer's and Parkinson's Diseases. Drug Development Research 77:8, pages 458-468.
Crossref
Crossref
Andrea Milelli, Eleonora Turrini, Elena Catanzaro, Francesca Maffei & Carmela Fimognari. (2016) Perspectives in Designing Multifunctional Molecules in Antipsychotic Drug Discovery. Drug Development Research 77:8, pages 437-443.
Crossref
Crossref
Chenjuan Tao, Weiwei Yan, Yuan Li & Xiaodong Lu. (2016) Effect of antidepressants on spatial memory deficit induced by dizocilpine. Psychiatry Research 244, pages 266-272.
Crossref
Crossref
Yoshiteru Takekita, Chiara Fabbri, Masaki Kato, Shinpei Nonen, Shiho Sakai, Naotaka Sunada, Yosuke Koshikawa, Masataka Wakeno, Gaku Okugawa, Toshihiko Kinoshita & Alessandro Serretti. (2015) HTR1A Gene Polymorphisms and 5-HT1A Receptor Partial Agonist Antipsychotics Efficacy in Schizophrenia. Journal of Clinical Psychopharmacology 35:3, pages 220-227.
Crossref
Crossref
Hao Tang, Caroline F. Dalton, Umarat Srisawat, Zhi Jun Zhang & Gavin P. Reynolds. (2013) Methylation at a transcription factor-binding site on the 5-HT1A receptor gene correlates with negative symptom treatment response in first episode schizophrenia. The International Journal of Neuropsychopharmacology 17:04, pages 645-649.
Crossref
Crossref
A. Carlo Altamura, Massimiliano Buoli & Sara Pozzoli. (2014) Role of immunological factors in the pathophysiology and diagnosis of bipolar disorder: Comparison with schizophrenia. Psychiatry and Clinical Neurosciences 68:1, pages 21-36.
Crossref
Crossref
Christine Wyss, Konrad Hitz, Michael P. Hengartner, Anastasia Theodoridou, Caitriona Obermann, Idun Uhl, Patrik Roser, Edna Grünblatt, Erich Seifritz, Georg Juckel & Wolfram Kawohl. (2013) The Loudness Dependence of Auditory Evoked Potentials (LDAEP) as an Indicator of Serotonergic Dysfunction in Patients with Predominant Schizophrenic Negative Symptoms. PLoS ONE 8:7, pages e68650.
Crossref
Crossref
Viktor P. Samokhvalov, Oksana E. Samokhvalova, Viktoria A. Verbenko & Georgij N. Verbenko. 2013. Polypharmacy in Psychiatry Practice, Volume II. Polypharmacy in Psychiatry Practice, Volume II
31
42
.
Saïd Kourrich, Tsung-Ping Su, Michiko Fujimoto & Antonello Bonci. (2012) The sigma-1 receptor: roles in neuronal plasticity and disease. Trends in Neurosciences 35:12, pages 762-771.
Crossref
Crossref
Olivia Frånberg, Monica M. Marcus & Torgny H. Svensson. (2012) Involvement of 5-HT2A receptor and α2-adrenoceptor blockade in the asenapine-induced elevation of prefrontal cortical monoamine outflow. Synapse 66:7, pages 650-660.
Crossref
Crossref
Seth Himelhoch, Eric Slade, Julie Kreyenbuhl, Deborah Medoff, Clayton Brown & Lisa Dixon. (2012) Antidepressant prescribing patterns among VA patients with schizophrenia. Schizophrenia Research 136:1-3, pages 32-35.
Crossref
Crossref
Monica M. Marcus, Kent Jardemark, Anna Malmerfelt, Jens Gertow, Åsa Konradsson-Geuken & Torgny H. Svensson. (2012) Augmentation by escitalopram, but not citalopram or R-citalopram, of the effects of low-dose risperidone: Behavioral, biochemical, and electrophysiological evidence. Synapse 66:4, pages 277-290.
Crossref
Crossref
Gavin P Reynolds. (2012) The Pharmacogenetics of Symptom Response to Antipsychotic Drugs. Psychiatry Investigation 9:1, pages 1.
Crossref
Crossref
Gavin P. Reynolds. 2012. Current Antipsychotics. Current Antipsychotics
213
239
.
Urs Meyer. (2011) Anti-inflammatory signaling in schizophrenia. Brain, Behavior, and Immunity 25:8, pages 1507-1518.
Crossref
Crossref
Urs Meyer, Markus J. Schwarz & Norbert Müller. (2011) Inflammatory processes in schizophrenia: A promising neuroimmunological target for the treatment of negative/cognitive symptoms and beyond. Pharmacology & Therapeutics 132:1, pages 96-110.
Crossref
Crossref
Maria Vares, Peter Saetre, Pontus Strålin, Sten Levander, Eva Lindström & Erik G. Jönsson. (2011) Concomitant medication of psychoses in a lifetime perspective. Human Psychopharmacology: Clinical and Experimental 26:4-5, pages 322-331.
Crossref
Crossref
David A. Favor, James J. Powers, Andrew D. White, Lawrence W. Fitzgerald, Vincent Groppi & Kevin A. Serpa. (2010) 6-Alkoxyisoindolin-1-one based dopamine D2 partial agonists as potential antipsychotics. Bioorganic & Medicinal Chemistry Letters 20:19, pages 5666-5669.
Crossref
Crossref
Norbert Müller. (2010) Dichotomie oder Kontinuum? Gemeinsamkeiten und Besonderheiten in Neurobiologie und Therapie affektiver und schizophrener Psychosen. Psychiatrie und Psychotherapie 6:3, pages 139-143.
Crossref
Crossref
Wayne E. ChildersJr.Jr. & David P. Rotella. 2010. Analogue-Based Drug Discovery II. Analogue-Based Drug Discovery II
269
295
.
Mathias Zink, Susanne Englisch & Andreas Meyer-Lindenberg. (2010) Polypharmacy in schizophrenia. Current Opinion in Psychiatry 23:2, pages 103-111.
Crossref
Crossref
S. Englisch, U. Knopf, B. Scharnholz, A. Kuwilsky, M. Deuschle & M. Zink. (2008) Duloxetine for major depressive episodes in the course of psychotic disorders: an observational clinical trial. Journal of Psychopharmacology 23:8, pages 875-882.
Crossref
Crossref
Marc ValentíJosefina Castro-FornielesMaría Luisa LázaroGisela SugrañesInmaculada Baeza. (2009) Simple Schizophrenia in an Adolescent. Journal of Child and Adolescent Psychopharmacology 19:5, pages 589-590.
Crossref
Crossref
David P. Rotella, Geraldine R. McFarlane, Alexander Greenfield, Cristina Grosanu, Albert J. Robichaud, Rajiah Aldrin Denny, Rolf W. Feenstra, Sara Núñez-García, Jan-Hendrik Reinders, Martina van der Neut, Andrew McCreary, Chris G. Kruse, Kelly Sullivan, Farhana Pruthi, Margaret Lai, Jean Zhang, Dianne M. Kowal, Tikva Carrick, Steven M. Grauer, Rachel L. Navarra, Radka Graf, Julie Brennan, Karen L. Marquis & Mark H. Pausch. (2009) Tetrahydrocarbazole-based serotonin reuptake inhibitor/dopamine D2 partial agonists for the potential treatment of schizophrenia. Bioorganic & Medicinal Chemistry Letters 19:19, pages 5552-5555.
Crossref
Crossref
Yehonala Gudlowski, Seza Özgürdal, Henning Witthaus, Jürgen Gallinat, Marta Hauser, Christine Winter, Idun Uhl, Andreas Heinz & Georg Juckel. (2009) Serotonergic dysfunction in the prodromal, first-episode and chronic course of schizophrenia as assessed by the loudness dependence of auditory evoked activity. Schizophrenia Research 109:1-3, pages 141-147.
Crossref
Crossref
Ryu Takizawa, Kenji Hashimoto, Mamoru Tochigi, Yuki Kawakubo, Kohei Marumo, Tsukasa Sasaki, Masato Fukuda & Kiyoto Kasai. (2009) Association between sigma-1 receptor gene polymorphism and prefrontal hemodynamic response induced by cognitive activation in schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry 33:3, pages 491-498.
Crossref
Crossref
Christine Winter, Teri J. Reutiman, Timothy D. Folsom, Reinhard Sohr, Rainer J. Wolf, Georg Juckel & S. Hossein Fatemi. (2008) Dopamine and serotonin levels following prenatal viral infection in mouse—Implications for psychiatric disorders such as schizophrenia and autism. European Neuropsychopharmacology 18:10, pages 712-716.
Crossref
Crossref
Masaomi Iyo, Yukihiko Shirayama, Hiroyuki Watanabe, Mihisa Fujisaki, Ryosuke Miyatake, Goro Fukami, Akihiro Shiina, Michiko Nakazato, Tetsuya Shiraishi, Tsuyoshi Ookami & Kenji Hashimoto. (2008) Fluvoxamine as a sigma-1 receptor agonist improved cognitive impairments in a patient with schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry 32:4, pages 1072-1073.
Crossref
Crossref
Masatomo Ishikawa, Kiichi Ishiwata, Kenji Ishii, Yuichi Kimura, Muneyuki Sakata, Mika Naganawa, Keiichi Oda, Ryousuke Miyatake, Mihisa Fujisaki, Eiji Shimizu, Yukihiko Shirayama, Masaomi Iyo & Kenji Hashimoto. (2007) High Occupancy of Sigma-1 Receptors in the Human Brain after Single Oral Administration of Fluvoxamine: A Positron Emission Tomography Study Using [11C]SA4503. Biological Psychiatry 62:8, pages 878-883.
Crossref
Crossref
Yujiro Kaneko, Atsushi Kashiwa, Takashi Ito, Sumikazu Ishii, Asami Umino & Toru Nishikawa. (2006) Selective Serotonin Reuptake Inhibitors, Fluoxetine and Paroxetine, Attenuate the Expression of the Established Behavioral Sensitization Induced by Methamphetamine. Neuropsychopharmacology 32:3, pages 658-664.
Crossref
Crossref
Kenji Hashimoto, Yuko Fujita & Masaomi Iyo. (2006) Phencyclidine-Induced Cognitive Deficits in Mice are Improved by Subsequent Subchronic Administration of Fluvoxamine: Role of Sigma-1 Receptors. Neuropsychopharmacology 32:3, pages 514-521.
Crossref
Crossref
Brendan P. Murphy, Young-Chul Chung, Tae-Won Park & Patrick D. McGorry. (2006) Pharmacological treatment of primary negative symptoms in schizophrenia: A systematic review. Schizophrenia Research 88:1-3, pages 5-25.
Crossref
Crossref
Cornelis J. Van der Schyf, Werner J. Geldenhuys & Moussa B. H. Youdim. (2006) Multifunctional drugs with different CNS targets for neuropsychiatric disorders. Journal of Neurochemistry 99:4, pages 1033-1048.
Crossref
Crossref
Tamar MozesTanya EbertSabbagh-Etun MichalBaruch SpivakAbraham Weizman. (2006) An Open-Label Randomized Comparison of Olanzapine Versus Risperidone in the Treatment of Childhood-Onset Schizophrenia. Journal of Child and Adolescent Psychopharmacology 16:4, pages 393-403.
Crossref
Crossref
Kurt Kroenke & Judith G.M. Rosmalen. (2006) Symptoms, Syndromes, and the Value of Psychiatric Diagnostics in Patients Who Have Functional Somatic Disorders. Medical Clinics of North America 90:4, pages 603-626.
Crossref
Crossref
Constantin Tranulis, Faycal Mouaffak, Laurent Chouchana, Emmanuel Stip, Raphael Gourevitch, Marie France Poirier, Jean-Pierre Olie??Henri Loo & David Gourion. (2006) Somatic Augmentation Strategies in Clozapine Resistance-What Facts?. Clinical Neuropharmacology 29:1, pages 34-44.
Crossref
Crossref
Roland Vauth & Rolf-Dieter Stieglitz. (2006) Der Stellenwert von Kombinationsbehandlung in der Versorgung schizophrener Störungen. Zeitschrift für Psychiatrie, Psychologie und Psychotherapie 54:3, pages 173-183.
Crossref
Crossref
Larissa Moutsimilli, Severine Farley, Sylvie Dumas, Salah El Mestikawy, Bruno Giros & Eleni T. Tzavara. (2005) Selective cortical VGLUT1 increase as a marker for antidepressant activity. Neuropharmacology 49:6, pages 890-900.
Crossref
Crossref
Diego Novick, Manuel Bousono, David Suarez, Jose M. Olivares, Angel L. Montejo, Josep Maria Haro, Eric T. Edgell & Mark Ratcliffe. (2005) Use of concomitant medication with antipsychotic treatment in outpatients with schizophrenia: Results from the European Schizophrenia Outpatients Health Outcomes (SOHO) study. Progress in Neuro-Psychopharmacology and Biological Psychiatry 29:6, pages 972-982.
Crossref
Crossref
. (2005) Current awareness in human psychopharmacology. Human Psychopharmacology: Clinical and Experimental 20:3, pages 217-224.
Crossref
Crossref